Business Context and Reporting Period
This Form 8-K is a current report filed by Histogenics Corporation (not Ocugen, Inc.) on October 10, 2017. The filing reports a corporate governance event involving the promotion of an executive officer and the execution of a new employment agreement.
Key Financial Metrics
The filing does not provide financial statements, revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation:
- Base Salary: $375,000 annual gross rate.
- Target Bonus: 40% of the annual base salary.
- Equity Grant: Option to purchase 50,000 shares of Common Stock.
Material Changes
The material change reported is the promotion of Stephen Kennedy to Executive Vice President and Chief Operating Officer, effective October 10, 2017. This change is accompanied by an amended and restated employment agreement detailing new compensation terms and an equity grant.
Guidance, Outlook, and Risks
The filing contains no financial guidance, outlook, or discussion of general business risks. The primary contingency noted is that the grant of the 50,000 stock options is subject to approval by the Company's board of directors or its compensation committee. The options vest over a four-year period, with 25% vesting on October 10, 2018.
Investor Verification Checklist
- Verify the correct registrant name is Histogenics Corporation, not Ocugen, Inc.
- Confirm the vesting schedule and exercise terms of the 50,000 stock options granted to Stephen Kennedy.
- Review the full text of the Amended and Restated Employment Agreement (Exhibit 10.39) for termination provisions and other covenants.
- Check subsequent filings to confirm board approval of the equity grant.